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Abstract 
Objective: 
Non-psychoactive phytocannabinoids (pCBs) from Cannabis sativa may represent 
novel therapeutic options for cachexia due to their pleiotropic pharmacological 
activities, including appetite stimulation. We have recently shown that purified 
cannabigerol (CBG) is a novel appetite stimulant in rats. As standardised extracts from 
Cannabis chemotypes dominant in one pCB (botanical drug substances (BDS)) often 
show greater efficacy and/or potency than purified pCBs, we investigated the effects of 
a CBG-rich BDS, devoid of psychoactive ∆9-THC, on feeding behaviour. 
Methods: 
Following a 2 hour pre-feed satiation procedure, 16 male Lister-hooded rats were 
administered CBG-BDS (at 30-240 mg/kg) or vehicle. Food intake, meal pattern 
microstructure and locomotor activity were recorded over 2 hours. 
Results: 
Total food intake was increased by 120 and 240mg/kg CBG-BDS vs vehicle (1.53g and 
1.36g, respectively, vs 0.56g; p<0.05 and p<0.01). Latency to feeding onset was dose-
dependently decreased by all doses (p<0.05-0.01), and 120 and 240mg/kg doses 
increased both the number of meals consumed (p<0.01) and cumulative size of the first 
2 meals (p<0.05 and p<.0.01). No significant effect was observed on ambulatory 
activity or rearing behaviour.  
Conclusions: 
CBG-BDS is a novel appetite stimulant, which may have greater potency than purified 
CBG, despite the absence of ∆9-THC in the extract.  
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Introduction 
There is an urgent unmet clinical need for well-tolerated pharmacotherapeutics for 
cancer- and chemotherapy-induced cachexia. Phytocannabinoids (pCBs) from 
Cannabis sativa may represent viable candidates for this indication, due to their 
pleiotropic pharmacological activities, including modulation of feeding behaviour, 
metabolic homeostasis and inflammation (Brodie et al. 2015).  
While the appetite-stimulating properties of C. sativa have historically been attributed to 
the psychoactive pCB ∆9-tetrahydrocannabinol (∆9-THC), we have previously shown 
that C. sativa extracts containing little or no ∆9-THC still stimulate appetite in rats 
(Farrimond et al. 2011), and that purified pCBs other than ∆9-THC can modulate 
feeding behaviours (Farrimond et al. 2012). Recent studies have investigated isolated 
non-psychoactive pCBs (with known anti-inflammatory and/or anti-tumour activities) for 
their ability to stimulate feeding, and thus their potential as novel cachexia treatments. 
One such pCB is cannabigerol (CBG), which attenuates inflammatory bowel disease 
and colon carcinogenesis in vivo (Borrelli et al. 2013; Borrelli et al. 2014) and has in 
vitro affinities for molecular targets involved in feeding and metabolic regulation (Cascio 
et al. 2010; De Petrocellis et al. 2011). Using our well-established pre-feed satiation 
paradigm, we have recently shown that purified CBG stimulates multiple components 
of feeding behaviour, without detrimental motoric side-effects (Brierley et al. 2016a). 
These previous data (reproduced here in Table 1 for reference), demonstrated that 
purified CBG (120-240 mg/kg) increased total food intake over a 2 hour test. CBG-
induced hyperphagia was predominantly due to increased appetitive behaviours, 
evidenced by increased frequency of feeding, rather than affects on meal sizes or 
durations.  
While testing the purified forms of pCBs is the rational first step in determining their 
pharmacological activities, in vitro and in vivo studies have shown that their botanical 
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drug substance (BDS) form may have greater efficacy and/or potency (De Petrocellis et 
al. 2011; Hill et al. 2013). Such BDSs (standardised extracts from chemotypes in which 
a particular pCB is dominant (de Meijer and Hammond 2005)), may exert differential 
effects to purified pCBs due to polypharmacology with the other low-abundance pCBs 
and/or terpenoids present, or via altered pharmacokinetics (Wagner and Ulrich-
Merzenich 2009). The present study was thus conducted to investigate the effects of a 
CBG-rich BDS (devoid of ∆9-THC) on feeding behaviours, using an identical pre-feed 
paradigm and dose range as that in our study of purified CBG.  
 
Methods 
The effects of CBG-BDS on feeding behaviour were investigated using our pre-feed 
satiation paradigm, as fully detailed in previous reports (Brierley et al. 2016a; Brierley 
et al. 2016b). All experiments were performed in accordance with UK Home Office 
regulations [Animals (Scientific Procedures) Act 1986].  
Drugs: 
CBG-BDS was supplied by GW Research (Salisbury, UK), containing 72.2% w/w CBG, 
trace additional phytocannabinoids (CBGV: 0.4%; CBGA: 0.3%; CBC: 0.7%) and a 
non-pCB fraction including terpenoids and residual plant matter. Notably, this BDS 
contained no ∆9-THC. CBG-BDS or sesame seed oil vehicle were orally administered 
to 16 Lister-hooded rats (Harlan, UK; 200-225g on delivery), using a within-subjects 
design. Animals thus received doses of 0,30,60,120 and 240mg/kg (absolute mass of 
CBG-BDS) according to a pseudo-random, counterbalanced Latin square protocol, with 
a ≥48 hour washout period.  
Procedure: 
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At dark photoperiod onset, animals began a 2 hour pre-feed procedure, during which 
they had access to highly palatable wet-mash feed. Animals were habituated to this 
procedure until stable pre-feed consumption levels were observed over 4 consecutive 
habituation days, determined by a non-significant effect of day (F3, 63=0.5603, p=0.644).  
On test days, animals completed the pre-feed procedure and were immediately 
administered CBG-BDS or vehicle and returned to home cages for 1 hour drug 
assimilation, during which food was unavailable. They were then placed into custom-
designed feeder cages (270mm x 405mm) for the 2 hour test, during which food 
consumption and locomotor activity were automatically recorded. Food intake monitors 
(TSE Systems, Germany) provided data on the time, duration and size of each feeding 
bout, which were combined into ‘meals’, defined as bouts consuming ≥0.5 g and 
separated by ≥900s. Two levels of infrared activity monitors (Ugo Basile, Italy) were 
arrayed alongside the feeder cages, such that ambulatory locomotor activity was 
quantified by horizontal beam breaks in a plane 20mm above the cage base, and 
rearing behaviour by vertical breaks in a plane 120mm high.  
Data Analysis:  
Data were analysed to provide measures of appetitive and consummatory behaviours, 
using the parameters of latency to first meal and meal number (appetitive) and meal 
size and duration (consummatory). Ambulatory activity and rearing were quantified 
using horizontal and vertical infrared beam breaks. Data were analysed by one-way 
repeated-measures ANOVA, with significant overall effects followed by planned 
comparisons of all dose groups vs vehicle. Non-parametric data were analysed by 
Friedman’s ANOVA and Wilcoxon’s signed rank comparisons. Results were considered 
significant if p<0.05.  
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Results  
Consistent with previously reported effects of purified CBG, CBG-BDS significantly 
increased total food intake during the test (Fig. 1A; F2.2, 33.2=3.841, p=0.028). Total 
intake was increased following administration of CBG-BDS  at 120mg/kg (F1, 15=8.230, 
p=0.012) and 240mg/kg (F1, 15=11.097, p=0.005), with animals consuming 1.53g 
(±0.39) and 1.36g (±0.39), respectively, compared to 0.56g (±0.26) vehicle intakes. 
Increased intake was predominantly driven by stimulation of appetitive feeding, 
evidenced by the dose-dependently decreased latency to feeding onset (Figs. 1B and 
2; Χ24=10.4221, p=0.034). All doses of CBG-BDS significantly decreased this latency, 
with maximal effects observed at 120mg/kg (Z=-2.805, p=0.005), which advanced 
feeding onset by approximately 40 minutes. Frequency of feeding was also increased, 
demonstrated by significantly increased number of meals (Fig. 1C; F4, 60=3.761, 
p=0.009). In contrast, while an increase in the cumulative size of the first two meals 
was observed (Table 1; F2.1, 32.7=3.353, p=0.044), the duration of meals, another 
measure of consummatory behaviour, was not significantly affected, including the 
cumulative duration of the first two meals (F1.8, 26.4=2.575, p=0.101) or of all meals 
combined (F1.9, 27.7=3.099, p=0.065). Corroborating the previously observed lack of 
detrimental motoric side-effects of purified CBG, CBG-BDS had no effect on either 
ambulatory activity (F4, 60=1.894, p=0.123) nor rearing (F4, 60=0.876, p=0.484) over the 2 
hour test (Table 2).  
 
Discussion 
CBG-BDS, at doses matched to our study of purified CBG, had similar effects on 
feeding patterns, despite the effective doses of CBG itself being approximately 30% 
lower. Overall, animals administered CBG-BDS began feeding sooner, consumed more 
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meals and consumed more within these meals. However, subtle differences were 
evident indicating that while CBG-BDS has similar efficacy in this paradigm, it has 
apparently greater potency than purified CBG in stimulating feeding behaviours. Total 
intake over the test duration was maximally increased by ~1g following doses of 
120mg/kg, a three-fold increase vs vehicle. Purified CBG elicited a similar maximal 
increase of ~1g, however this only represented a two-fold increase and was seen 
following 240 mg/kg doses. Appetitive feeding behaviour, measured by decreased 
latency to feeding onset, was dose-dependently stimulated by all doses of CBG-BDS, 
with a maximal reduction at 120mg/kg of ~40 minutes. In contrast, purified CBG only 
significantly advanced feeding onset at 240mg/kg, by ~30 minutes. Both the number of 
meals and cumulative size of the first two meals were approximately doubled by both 
120 and 240 mg/kg CBG-BDS, in this case demonstrating a consistent pattern of 
feeding stimulation to purified CBG. It is thus apparent that CBG-BDS is similarly 
efficaceous to purified CBG at stimulating feeding behaviours, but as the maximal 
effects were seen following doses of 120 mg/kg, it may be more potent, and 
demonstrates a ceiling effect not seen following purified CBG.     
Although determining the mechanism of action for this hyperphagia was beyond the 
scope of these studies, we have previously speculated on putative mechanisms based 
on the published in vitro affinities and activities of CBG (Brierley et al. 2016a). In light of 
the apparent greater potency of CBG-BDS, such speculation can be extended based 
on the differential affinities and activities reported in comparative in vitro studies of the 
purified and BDS forms (De Petrocellis et al. 2011). While both have little affinity or 
activity at cannabinoid 1 or 2 receptors, they have similar efficacy as inhibitors of 
anandamide (AEA) reuptake, and may thus elicit hyperphagia via upregulation of 
orexigenic endocannabinoid tone. CBG-BDS has four-fold greater potency as an 
inhibitor of monoacylglycerol lipase (De Petrocellis et al. 2011), the hydrolytic enzyme 
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for 2-arachidonoylglycerol (2-AG). Given that 2-AG also elicits hyperphagia (Kirkham et 
al. 2002), it is possible that the increased potency of CBG-BDS is due to concurrent 
elevation of 2-AG and AEA.  The apparent ceiling effect of CBG-BDS at 120 mg/kg, not 
observed for purified CBG, also points to the potential involvment of another 
mechanism, involving the endocannabinoid-degrading enzyme N-acylethanolamine 
acid amide hydrolase (NAAA). While neither forms of CBG have appreciable activity as 
fatty acid amid hydrolase (FAAH) inhibitors, CBG-BDS alone is a potent inhibitor of 
NAAA, which would result in a selective inhibition of palmitoylethanolamine (PEA) 
hydrolysis over AEA. Given that PEA attenuates hyperphagia (Mattace Raso et al. 
2014), it is plausible that at CBG-BDS doses >120mg/kg, PEA is elevated to 
physiologically-relevant levels, attenuating CBG-induced hyperphagia mediated by 
other mechanisms. While neither the minor pCBs nor terpenoids present in CBG-BDS 
have known appetite-stimulating properties per se, they may improve the bioavailability 
of CBG and hence contribute to the apparent greater potency of the BDS via 
pharmacokinetic effects (Wagner and Ulrich-Merzenich 2009). Indeed, a recent study 
of the anticonvulsant effects of cannabidivarin-BDS demonstrated that a pCB-free BDS 
was without intrinsic effect, but apparently slightly increased efficacy of the purified 
pCB, supporting such a pharmacokinetic effect (Hill et al. 2013). While no direct 
pharmacokinetic comparison of purifed CBG and CBG-BDS has been published to 
date, it should be noted that purified forms of several major pCBs have shown 
differential brain concentrations dependent on route of admininistration, with CBG 
reaching higher concentrations via the intraperitoneal route, in contrast to cannbidiol 
and CBDV for which the oral route was more effective (Deiana et al. 2012). Further 
studies investigating the effects of intraperitoneal purified CBG and CBG-BDS on 
feeding behaviours may thus be warranted to determine which form, dose level and 
route of administration may have the greatest translational potential for cachexia.    
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Conclusion 
Here we report for the first time that a CBG-rich BDS, devoid of ∆9-THC or other pCBs 
with known hyperphagic activity, stimulates appetite in pre-satiated rats. CBG-BDS 
appears to have similar efficacy but greater potency than purified CBG, and warrants 
investigation as a potential novel treatment for cachexia. 
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CBG-BDS Behavioural Pharmacology Full Report – Figures 
 
 
Figure 1. Total food intake (A) and meal pattern microstructure parameters of 
latency to feeding onset (B) and number of meals consumed (C). Data 
presented as group mean ± SEM, analysed by one-way repeated measures 
ANOVA (latency by Friedman’s ANOVA) and planned comparisons of all dose 
groups vs vehicle. * p < 0.05, ** p < 0.01. 
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Figure 2. Graphical summary of group mean meal pattern microstructure 
parameters for meals 1 and 2. Boxes are positioned along x-axis according to 
meal latencies, box widths are scaled to meal durations and meal sizes are 
given above. Where individual animals did not consume a second meal, 
minimum (size and duration) or maximum (latency) values were imputed. 
Asterisks indicate significantly decreased latencies compared to vehicle, * p < 
0.05, ** p < 0.01.    
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 CBG-BDS (mg/kg, p.o.) Purified CBG (mg/kg, p.o.)† 
 0 30 60 120 240 0 30 60 120 240 
Hour 1 Consumption (g) 
0.21 
(± 0.18) 
0.29 
(± 0.20) 
0.52 
(± 0.26) 
0.70 
(± 0.27) 
0.57 
(± 0.22) 
0.47 
(± 0.22) 
0.40 
(± 0.25) 
0.55 
(± 0.25) 
1.06 
(± 0.30) 
0.89 
(± 0.25) 
Hour 2 Consumption (g) 
0.35 
(± 0.18) 
0.64 
(± 0.23) 
0.08 
(± 0.06) 
0.83 
(± 0.21) 
0.78 
(± 0.27) 
0.38 
(± 0.18) 
0.49 
(± 0.20) 
0.46 
(± 0.17) 
0.59 
(± 0.15) 
  0.99 ** 
(± 0.19) 
Total Consumption (g) 
0.56 
(± 0.26) 
0.93 
(± 0.29) 
0.60 
(± 0.27) 
  1.53 * 
(±0.39) 
    1.36 ** 
(±0.39) 
0.85 
(± 0.28) 
0.89 
(± 0.40) 
1.01 
(± 0.29) 
  1.66 * 
(± 0.37) 
  1.89 ** 
(± 0.38) 
Latency to 1st Meal (min) 
108.9 
(± 7.4) 
   95.1 * 
(± 9.0) 
   84.1 * 
(± 11.9) 
   71.1 ** 
(± 12.7) 
    74.3 * 
(± 11.8) 
83.3 
(± 12.5) 
93.7 
(± 11.0) 
78.9 
(± 11.2) 
59.1 
(± 12.0) 
  54.3 * 
(± 13.2) 
Latency to 2nd Meal (min) 
112.9 
(± 5.1) 
107.7 
(± 7.3) 
105.6 
(± 8.2) 
95.6 
(± 9.4) 
95.8 
(± 8.7) 
105.3 
(± 8.7) 
108.2 
(± 6.8) 
106.4 
(± 5.4) 
95.7 
(± 8.3) 
92.1 
(± 8.5) 
Number of Meals 
0.50 
(± 0.22) 
0.69 
(± 0.24) 
0.63 
(± 0.20) 
    1.13 ** 
(± 0.24) 
   1.19 ** 
(± 0.31) 
0.63 
(± 0.20) 
0.75 
(± 0.32) 
1.00 
(± 0.26) 
 1.44 * 
(± 0.33) 
   1.44 ** 
(± 0.29) 
Meal 1 Size (g) 
0.29 
(± 0.12) 
0.59 
(± 0.19) 
0.32 
(± 0.11) 
0.86 
(± 0.22) 
0.59 
(± 0.16) 
0.65 
(± 0.23) 
0.38 
(± 0.16) 
0.57 
(± 0.19) 
0.93 
(± 0.18) 
1.04 
(± 0.23) 
Meal 2 Size (g) 
0.19 
(± 0.13) 
0.26 
(± 0.14) 
0.29 
(± 0.17) 
0.59 
(± 0.21) 
0.57 
(± 0.21) 
0.20 
(± 0.11) 
0.30 
(± 0.15) 
0.22 
(± 0.09) 
0.57 
(± 0.23) 
0.64 
(± 0.18) 
Meal 1 + 2 Size (g) 
0.48 
(± 0.21) 
0.85 
(± 0.26) 
0.61 
(± 0.27) 
  1.45 * 
(± 0.37) 
   1.16 ** 
(± 0.32) 
0.85 
(± 0.28) 
0.68 
(± 0.30) 
0.79 
(± 0.24) 
1.51 
(± 0.31) 
  1.68 * 
(± 0.34) 
Meal 1 Duration (min) 
0.9 
(± 0.5) 
2.8 
(± 0.9) 
1.4 
(± 0.7) 
4.7 
(± 1.7) 
3.9 
(± 1.6) 
5.9 
(± 2.7) 
1.1 
(± 0.7) 
3.1 
(± 1.2) 
4.0 
(± 1.1) 
5.9 
(± 1.9) 
Meal 2 Duration (min) 
0.8 
(± 0.7) 
0.9 
(± 0.7) 
1.1 
(± 0.6) 
3.0 
(± 1.6) 
2.0 
(± 0.9) 
0.3 
(± 0.2) 
0.8 
(± 0.5) 
0.5 
(± 0.3) 
2.4 
(± 1.5) 
2.9 
(± 1.1) 
Meal 1 + 2 Duration (min) 
1.7 
(± 0.9) 
3.6 
(± 1.1) 
2.5 
(± 1.2) 
7.7 
(± 2.9) 
5.9 
(± 2.0) 
6.2 
(± 2.7) 
1.9 
(± 1.1) 
3.6 
(± 1.3) 
6.4 
(± 1.8) 
8.7 
(± 2.3) 
All Meals Duration (min) 
1.8 
(± 0.9) 
3.7 
(± 1.1) 
2.5 
(± 1.2) 
8.5 
(± 2.9) 
6.4 
(± 2.2) 
6.2 
(± 2.7) 
3.0 
(± 1.5) 
3.6 
(± 1.3) 
8.7 
(± 2.7) 
9.1 
(± 2.3) 
Table 1. Hourly food consumption and meal pattern analysis data. Data presented as 
group mean ± SEM, analysed by one-way repeated measures ANOVA and planned 
comparisons of all dose groups vs vehicle. All groups n = 16, * p < 0.05, ** p < 0.01. † 
Data for purified CBG has been previously published (Brierley et al. 2016a), and is 
reproduced here for comparison with CBG-BDS.  
 
